miR-1297 promotes apoptosis and inhibits the proliferation and invasion of hepatocellular carcinoma cells
by targeting HMGA2

Liu,Yu; Liang,Hongyan; Jiang,Xiaofeng

doi:10.3892/ijmm.2015.2341

miR-1297 promotes apoptosis and inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting HMGA2

Authors:
- Yu Liu
- Hongyan Liang
- Xiaofeng Jiang
View Affiliations

Affiliations: Department of Laboratory Medicine, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
Published online on: September 10, 2015 https://doi.org/10.3892/ijmm.2015.2341
Pages: 1345-1352

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) have recently emerged as important regulators of gene expression in various tissues. In particular, miRNAs have been identified as new therapeutic agents and biomarkers in cancer. The aim of the present study was to explore whether miR‑1297 has an anti‑cancer role in hepatocellular carcinoma cell lines and to explore its underlying mechanism. The proliferation, apoptosis and migration of hepatocellular carcinoma cells were evaluated by cell viability assay, TUNEL staining and a wound healing assay, respectively. Western blot analysis and reverse transcription polymerase chain reaction (RT‑PCR) were performed to determine the expression levels of proteins and mRNAs of high‑mobility group AT‑hook 2 (HMGA2) in hepatocellular carcinoma. The luciferase assay was employed to verify the inhibitory activity of miR‑1297 on the 3' untranslated region (3'UTR) of the HMGA2 gene. In the present study, overexpression of miR‑1297 significantly inhibited the proliferation of HepG2 and SMMC7721 cells. Forced expression of miR‑1297 also increased the apoptosis of HepG2 and SMMC7721. Furthermore, the migration of HepG2 and SMMC7721 was also clearly suppressed by miR‑1297 overexpression. All these effects can be abrogated by co‑transfection with miR‑1297 inhibitor‑AMO‑1297. The luciferase assay verified that miR‑1297 overexpression is able to inhibit the activity of luciferase reporter harboring the HMGA2 3'UTR, indicating HMGA2 as the target of miR‑1297. Although the HMGA2 level was not affected by miR‑1297, the HMGA2 protein was significantly inhibited by miR‑1297 overexpression. Collectively, miR‑1297 was revealed to regulate the proliferation, apoptosis and migration of hepatocellular carcinoma cells via acting on HMGA2. The finding provides a new target for the treatment of hepatocellular carcinoma.

View Figures

View References

1	Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, et al: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 24:1898–1903. 2006. View Article : Google Scholar : PubMed/NCBI
2	Aravalli RN, Cressman EN and Steer CJ: Cellular and molecular mechanisms of hepatocellular carcinoma: An update. Arch Toxicol. 87:227–247. 2013. View Article : Google Scholar
3	Ma WL, Jeng LB, Lai HC, Liao PY and Chang C: Androgen receptor enhances cell adhesion and decreases cell migration via modulating β1-integrin-AKT signaling in hepatocellular carcinoma cells. Cancer Lett. 351:64–71. 2014. View Article : Google Scholar : PubMed/NCBI
4	Ng L, Tung-Ping Poon R, Yau S, Chow A, Lam C, Li HS, Chung-Cheung Yau T, Law WL and Pang R: Suppression of actopaxin impairs hepatocellular carcinoma metastasis through modulation of cell migration and invasion. Hepatology. 58:667–679. 2013. View Article : Google Scholar : PubMed/NCBI
5	Villanueva A, Chiang DY, Newell P, et al: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 135:1972–1983. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhong W, Qin S, Zhu B, Pu M, Liu F, Wang L, Ye G, Yi Q and Yan D: Oxysterol-binding protein (OSBP)-related protein 8 (ORP8) increases sensitivity of hepatocellular carcinoma cells to Fas-mediated apoptosis. J Biol Chem. Jan 16–2015.Epub ahead of print. View Article : Google Scholar
7	Williams AH, Liu N, van Rooij E and Olson EN: MicroRNA control of muscle development and disease. Curr Opin Cell Biol. 21:461–469. 2009. View Article : Google Scholar : PubMed/NCBI
8	Divakaran V and Mann DL: The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res. 103:1072–1083. 2008. View Article : Google Scholar : PubMed/NCBI
9	van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA and Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 105:13027–13032. 2008. View Article : Google Scholar : PubMed/NCBI
10	van Rooij E, Liu N and Olson EN: MicroRNAs flex their muscles. Trends Genet. 24:159–166. 2008. View Article : Google Scholar : PubMed/NCBI
11	Frost RJ and van Rooij E: miRNAs as therapeutic targets in ischemic heart disease. J Cardiovasc Transl Res. 3:280–289. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lin Z, Murtaza I, Wang K, Jiao J, Gao J and Li PF: miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci USA. 106:12103–12108. 2009. View Article : Google Scholar : PubMed/NCBI
13	Yu L, Zhou L, Cheng Y, Sun L, Fan J, Liang J, Guo M, Liu N and Zhu L: MicroRNA-543 acts as an oncogene by targeting PAQR3 in hepatocellular carcinoma. Am J Cancer Res. 4:897–906. 2014.PubMed/NCBI
14	Zhang S, Shan C, Kong G, Du Y, Ye L and Zhang X: MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK). Oncogene. 31:3607–3620. 2012. View Article : Google Scholar
15	He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH and Lin JS: MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 31:3357–3369. 2012. View Article : Google Scholar
16	Li D, Liu Y, Li H, Peng JJ, Tan Y, Zou Q, Song XF, Du M, Yang ZH, Tan Y, et al: MicroRNA-1 promotes apoptosis of hepatocarcinoma cells by targeting apoptosis inhibitor-5 (API-5). FEBS Lett. 589:68–76. 2015. View Article : Google Scholar
17	Chen P, Wang BL, Pan BS and Guo W: MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2. Asian Pac J Cancer Prev. 15:9185–9190. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhang C, Chi YL, Wang PY, Wang YQ, Zhang YX, Deng J, Lv CJ and Xie SY: miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2. PLoS One. 7:e460902012. View Article : Google Scholar : PubMed/NCBI
19	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
20	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
21	Meng X, Franklin DA, Dong J and Zhang Y: MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res. 74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ying TH, Tsai JH, Wu TT, Tsai MT, Su WW, Hsieh YS and Liu JY: Immunochemical localization of protein kinase Calpha in the biopsies of human hepatocellular carcinoma. Chin J Physiol. 51:269–274. 2008.
23	Muche S, Kirschnick M, Schwarz M and Braeuning A: Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells. Anticancer Res. 34:4677–4683. 2014.PubMed/NCBI
24	Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, Finegold MJ and Huff V: β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. Cancer Res. 74:4515–4525. 2014. View Article : Google Scholar : PubMed/NCBI
25	Wang J, Park JS, Wei Y, Rajurkar M, Cotton JL, Fan Q, Lewis BC, Ji H and Mao J: TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function. Mol Cell. 51:211–225. 2013. View Article : Google Scholar : PubMed/NCBI
26	Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K: HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, et al: HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA. 110:9920–9925. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zaidi MR, Okada Y and Chada KK: Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res. 66:7453–7459. 2006. View Article : Google Scholar : PubMed/NCBI
29	Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z and You T: HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett. 355:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
30	Luo Y, Li W and Liao H: HMGA2 induces epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells. Oncol Lett. 5:1353–1356. 2013.PubMed/NCBI
31	Pentimalli F, Dentice M, Fedele M, Pierantoni GM, Cito L, Pallante P, Santoro M, Viglietto G, Dal Cin P and Fusco A: Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. Cancer Res. 63:7423–7427. 2003.PubMed/NCBI